HomeGMAB • NASDAQ
Genmab A/S - ADR
$29.91
After Hours:
$29.91
(0.00%)0.00
Closed: Mar 28, 5:20:00 PM GMT-4 · USD · NASDAQ · Disclaimer
US listed security
Previous close
$30.63
Day range
$29.84 - $30.56
Year range
$26.32 - $43.00
Market cap
19.54B USD
Avg Volume
626.22K
Financials
Income Statement
Revenue
Net income
(DKK)Dec 2023Y/Y change
Revenue
4.68B-8.94%
Operating expense
2.88B14.18%
Net income
640.00M24.51%
Net profit margin
13.6836.66%
Earnings per share
0.14-98.42%
EBITDA
1.73B-35.13%
Effective tax rate
30.89%
Total assets
Total liabilities
(DKK)Dec 2023Y/Y change
Cash and short-term investments
28.14B26.03%
Total assets
35.29B17.17%
Total liabilities
3.68B29.68%
Total equity
31.61B
Shares outstanding
65.33M
Price to book
0.06
Return on assets
11.84%
Return on capital
12.99%
Net change in cash
(DKK)Dec 2023Y/Y change
Net income
640.00M24.51%
Cash from operations
1.67B320.10%
Cash from investing
-442.00M-225.00%
Cash from financing
-22.00M-116.79%
Net change in cash
594.00M222.73%
Free cash flow
1.37B547.23%
About
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, USA, and Genmab K.K. in Tokyo, Japan. Genmab is a dual-listed company with shares traded on both the Copenhagen Stock Exchange in Denmark and the NASDAQ Global Select Market in the US. The company has 8 approved antibodies used in 8 marketed products, covering cancer indications and autoimmune diseases. Proprietary, marketed with partners: Epkinly/Tepkinly for the treatment of Relapsed/refractory diffuse large B-cell lymphoma Tivdak for the treatment of previously treated recurrent or metastatic cervical cancer Marketed by partners: Darzalex (IV) / Darzalex Faspro for the treatment of all stages of multiple myeloma as combination therapy or monotherapy, and for the treatment of newly diagnosed amyloid light-chain amyloidosis Kesimpta for the treatment of relapsing remitting multiple sclerosis Rybrevant for the treatment of non-small-cell lung cancer Wikipedia
Founded
1999
Website
Employees
2,204
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu